Altimmune to Present Pemvidutide Data at AASLD 2026

The company says an oral presentation will include new preclinical data showing reduced alcohol intake with pemvidutide. It also cited Phase 2b IMPACT findings of improved liver fibrosis and inflammation, with generally favorable gastrointestinal tolerability.